# A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558

> **NCT05840952** · PHASE1 · COMPLETED · sponsor: **Aligos Therapeutics** · enrollment: 90 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** ALG-097558
- **DRUG:** Placebo
- **DRUG:** Midazolam
- **DRUG:** Itraconazole
- **DRUG:** Carbamazepine
- **DRUG:** ALG-097558 in solution formulation
- **DRUG:** ALG-097558 in tablet formulation

## Key facts

- **NCT ID:** NCT05840952
- **Lead sponsor:** Aligos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-04
- **Primary completion:** 2024-04-29
- **Final completion:** 2024-04-29
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05840952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05840952, "A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05840952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*